)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
FibroBiologics (FBLG) investor relations material
FibroBiologics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary31 Jul, 2025
Executive summary
Focused on developing fibroblast-based therapies for chronic diseases, with lead candidates in wound healing, multiple sclerosis, degenerative disc disease, and psoriasis; no product revenue to date.
Completed preclinical studies for CYWC628 and CYMS101, with a Phase 1/2 trial for diabetic foot ulcers in Australia planned for Q1 2026.
Formed an Australian subsidiary to sponsor clinical trials and completed manufacturing of master and working cell banks for CYWC628.
Closed third $5 million tranche of $25 million financing to fund R&D and clinical trials.
Appointed new CFO with over 25 years of experience and engaged a consultant for strategic advisory and capital raising support.
Financial highlights
Net loss of $4.7 million for Q2 2025 and $9.6 million for the six months ended June 30, 2025, compared to $0.9 million net income and $7.6 million net loss in prior year periods.
Operating expenses increased to $4.5 million in Q2 2025 from $3.2 million in Q2 2024, driven by higher R&D and administrative costs.
Research and development expenses rose to $3.8 million for the six months ended June 30, 2025, up from $1.9 million year-over-year.
General and administrative expenses were $2.4 million in Q2 2025 and $5.2 million for the six months ended June 30, 2025.
Cash and cash equivalents were $8.8 million as of June 30, 2025, down from $14.0 million at year-end 2024.
Outlook and guidance
Expects to continue incurring significant losses as R&D and clinical activities expand; no product revenue anticipated in the near term.
Plans to initiate a Phase 1/2 clinical trial for CYWC628 in Australia in Q1 2026, with completion targeted for Q3 2026, pending resolution of manufacturing issues.
Pre-clinical IND-enabling studies for psoriasis treatment CYPS317 to be completed by end of 2025.
Ongoing need for additional capital to fund operations; substantial doubt exists about ability to continue as a going concern without further financing.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next FibroBiologics earnings date
Q3 202511 Nov, 2025
Next FibroBiologics earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
FibroBiologics Inc. is a biotechnology company that specializes in regenerative medicine and cell therapy. The company is focused on developing innovative treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds over 150 U.S. and international patents and patents pending, covering various clinical pathways including orthopedics, multiple sclerosis, psoriasis, wound healing, and cancer. The company is headquartered in Houston, Texas, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage